Alumis (ALMS) Joins Growth Indices, Is The Stock Overvalued?

Index shifts put Alumis stock in the growth spotlight

Alumis (ALMS) has been reshuffled across the Russell family of indices, dropped from several value and microcap benchmarks and added to multiple growth oriented indices on June 27, 2026.

These changes can influence how index funds and quantitative strategies treat Alumis stock, since many of them track specific style and size benchmarks. For you, the key question is what a stronger association with growth indices implies for its risk profile and trading behavior.

See our latest analysis for Alumis.

Those index moves come after a sharp run in Alumis stock, with the latest close at $26.64, a 1 month share price return of 31.04% and a year to date share price return of 197.49%. The 1 year total shareholder return is very large at about 7x, suggesting strong momentum despite a 1 day share price decline of 5.33%.

If you are comparing Alumis with other high growth stories in the sector, it can help to scan a broader set of biopharma focused ideas through a healthcare AI themed stock list such as 39 healthcare AI stocks

With Alumis now trading at $26.64, recent style index shifts and a price that sits well below the $40.10 analyst target raise a basic question for you: is there still a buying opportunity here, or is future growth already priced in?

Preferred Price-to-Book multiple of 6x: Is it justified?

On a simple yardstick, Alumis trades on a P/B of 6x, which sits alongside a strong share price run and its current $26.64 level.

The price to book ratio compares the stock price with the accounting value of net assets on the balance sheet. For a clinical stage biopharma company like Alumis, that figure often reflects cash and accumulated R&D, while the market price also tries to capture expectations for future drug approvals and commercialization that are not yet reflected in earnings.

Here, the P/B of 6x is higher than the US pharmaceuticals industry average of 2.3x and also above the 5.4x average for peers. That signals investors are currently paying a premium to the sector and to Alumis specific peer group for exposure to its autoimmune pipeline and expected revenue growth profile, even though the company is still reporting losses and is forecast to remain unprofitable over the next three years. See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 6x (OVERVALUED).

However, Alumis still carries clear risks, including ongoing losses of $237.415 million and reliance on successful clinical progress for its autoimmune and thyroid eye disease programs.

Find out about the key risks to this Alumis narrative.

Next Steps

With both risks and potential rewards in play for Alumis, it makes sense to look closely at the full picture and respond quickly with your own assessment. You can start with the 1 key reward and 2 important warning signs.

Looking for more Alumis style investment ideas?

If you want a broader context around Alumis, do not sit on the sidelines. Use the Simply Wall St Screener to spot other opportunities that match your style and risk comfort.

• Target potential bargain opportunities by scanning a curated list of companies that currently screen as attractively priced with solid fundamentals through the 41 high quality undervalued stocks.
• Strengthen the income side of your portfolio by focusing on companies offering higher yields and robust payout profiles using the 8 dividend fortresses.
• Prioritise resilience and capital protection by filtering for businesses that currently stand out with steadier risk characteristics via the 73 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com